Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999–2014)

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Circulation

• Publication date

  2018-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.117.032321PMID 29581125PMCID PMC6381601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Classification and Diagnosis of Diabetes.

  2022cited by this paper
• Cascade Screening for Familial Hypercholesterolemia and the Use of Genetic Testing.

  2017cited by this paper
• Rate of Statin Prescription in Younger Patients With Severe Dyslipidemia

  2017cited by this paper
• 9. Cardiovascular Disease and Risk Management.

  2017cited by this paper
• 2. Classification and Diagnosis of Diabetes.

  2017cited by this paper
• What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a National Primary Care Database.

  2016cited by this paper
• Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature.

  2016cited by this paper
• Familial hypercholesterolemia in a large ambulatory population: Statin use, optimal treatment, and identification for advanced medical therapies.

  2016cited by this paper
• Long-Term Risk of Atherosclerotic Cardiovascular Disease in US Adults With the Familial Hypercholesterolemia Phenotype

  2016cited by this paper
• Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland

  2016cited by this paper
• Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality.

  2016cited by this paper
• Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.

  2016cited by this paper
• Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry

  2016cited by this paper
• Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)

  2016cited by this paper
• The Agenda for Familial Hypercholesterolemia: A Scientific Statement From the American Heart Association.

  2015cited by this paper
• Systematic detection of familial hypercholesterolaemia in primary health care: a community based prospective study of three methods.

  2015cited by this paper
• Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.

  2015cited by this paper
• Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.

  2015cited by this paper
• Faculty Opinions recommendation of Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

  2014cited by this paper
• Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation.

  2014cited by this paper
• Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• National health and nutrition examination survey: analytic guidelines, 1999-2010.

  2013cited by this paper
• Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease

  2013cited by this paper
• Trends in lipids and lipoproteins in US adults, 1988-2010.

  2012cited by this paper
• Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.

  2012cited by this paper
• Familial hypercholesterolemia

  2011cited by this paper
• Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era

  2011cited by this paper
• Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

  2011cited by this paper
• Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

  2011cited by this paper
• Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project

  2010cited by this paper
• The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

  2009cited by this paper
• Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

  2008cited by this paper
• Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

  2008cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• HUMAN GENOME EPIDEMIOLOGY (HuGE) REVIEWS Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review

  2004cited by this paper
• Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality.

  2001cited by this paper
• Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.

  1999cited by this paper
• Determinants of cholesterol screening and treatment patterns. Insights for decision-makers.

  1998cited by this paper
• Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.

  1990influential reference
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper

• Association between the atherogenic index of plasma and cognitive impairment.

  2026cites this paper
• U-shaped association between TC/HDL-C ratio and the risk of metabolic dysfunction-associated fatty liver disease in older adults

  2026cites this paper
• 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.

  2026cites this paper
• Association between atherogenic index of plasma and stroke risk: A cross-sectional analysis of NHANES data

  2026cites this paper
• Treatment of severe hyperlipidemia and associated cardiovascular outcomes: Data from a large healthcare system.

  2025cites this paper
• American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults with Dyslipidemia - 2025 Update.

  2025cites this paper
• Association between the atherogenic index of plasma and mortality in the chronic kidney disease population: evidence from NHANES

  2025cites this paper
• The association between monocyte-to-high-density lipoprotein cholesterol ratio and type 2 diabetes mellitus: a cross-sectional study

  2025cites this paper
• Prevalence of Familial Hypercholesterolemia in Pakistan: A Pooled Analysis of 1.5 Million Individuals and Comparison with Other Countries of the Region

  2025cites this paper
• Associations between indicators of lipid and glucose metabolism and hypothyroidism

  2025cites this paper
• The role of three glucose/lipid composite indices (CHG, TYG, and AIP) in predicting carotid plaque and fatty liver outcomes: a retrospective cohort study

  2025cites this paper
• Where we work correlates with whether we receive cardiorespiratory preventive care services: Health and Retirement Study 2003–2018

  2025cites this paper
• Advances in Non-statin Lipid Therapies: A Narrative Review of Evolving Strategies for Cardiovascular Risk Reduction

  2025cites this paper
• U-shaped association between TC/HDL-C ratio and osteoporosis risk in older adults

  2025cites this paper
• Beyond identification of familial hypercholesterolemia: Improving downstream visits and treatments in a large health care system

  2025cites this paper
• 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

  2025cites this paper
• The Association Between the Atherogenic Index of Plasma and Cognitive Function: Evidence From the NHANES 2011–2014

  2025cites this paper
• Novel strategies to FIND people living with genetic dyslipidemias: The family heart foundation flag, identify, network, and deliver (FIND) familial hypercholesterolemia collaborative learning network

  2025cites this paper
• Association of C-reactive protein-to-lymphocyte ratio (CLR) with liver stiffness measurement (LSM): Findings from NHANES 2017 to 2018

  2025cites this paper
• Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data

  2024cites this paper
• Cardiometabolic index and mortality risks: elevated cancer and reduced cardiovascular mortality risk in a large cohort

  2024cites this paper
• Exploring the impact of insurance switching on the cost-effectiveness of population genetic screening for familial hypercholesterolemia to US payers.

  2024cites this paper
• Dietary Intake of Chromista Oil Alters Hepatic Metabolomic Profile of Mice With Excess Fat Mass

  2024cites this paper
• 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.

  2024cites this paper
• The influence of sex on heart failure mortality

  2024cites this paper
• Association between atherogenic index of plasma and all-cause mortality and specific-mortality: a nationwide population‑based cohort study

  2024cites this paper
• Postmarketing Reports of Incomplete Dosing-Related Complications with Self-Injected PCSK9 Inhibitors: A Descriptive Study and Disproportionality Analysis

  2024cites this paper
• Genetic testing for familial hypercholesterolemia

  2024cites this paper
• Combining bioinformatics and multiomics strategies to investigate the key microbiota and active components of Liupao tea ameliorating hyperlipidemia.

  2024cites this paper
• The association between monocyte-to-high-density lipoprotein ratio and hyperuricemia: Results from 2009 to 2018

  2024cites this paper
• Subclinical Atherosclerosis to Guide Treatment in Dyslipidemia and Diabetes Mellitus

  2024cites this paper
• An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients.

  2024cites this paper
• Family cascade screening for equitable identification of familial hypercholesterolemia: study protocol for a hybrid effectiveness-implementation type III randomized controlled trial

  2024cites this paper
• Prevalence and management of dyslipidemia in primary care practices in Canada

  2024cites this paper
• Effect of clinical decision support for severe hypercholesterolemia on low-density lipoprotein cholesterol levels

  2024cites this paper
• Life's essential 8 metrics and mortality outcomes in insulin resistance: The role of inflammation, vascular aging, and gender.

  2024cites this paper
• Modifiable and Non-Modifiable Risk Factors for Premature Coronary Heart Disease (PCHD): Systematic Review and Meta-Analysis.

  2024cites this paper
• Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol.

  2024cites this paper
• 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

  2024cites this paper
• Trends of Lipid Concentrations, Awareness, Evaluation, and Treatment in Severe Dyslipidemia in US Adults.

  2024cites this paper
• Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

  2023cites this paper
• Familial Hypercholesterolemia Biomarker Distribution in Dried Blood Spots.

  2023cites this paper
• Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort

  2023cites this paper
• Development and Validation of the American Heart Association’s PREVENT Equations

  2023cites this paper
• Survival Benefit and Cost Effectiveness of a Future Blood‐Based Diagnostic Test to Detect Cerebral Aneurysm Formation

  2023cites this paper
• Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets.

  2023cites this paper
• The association between atherogenic index of plasma and all-cause mortality and cardiovascular disease-specific mortality in hypertension patients: a retrospective cohort study of NHANES

  2023cites this paper
• Effect of overall lifestyle on the all-cause mortality and cardiovascular disease death in dyslipidemia patients with or without lipid-lowering therapy: a cohort study

  2023influential citation
• The mediating effect of depression on the relationship between osteoarthritis and cardiovascular disease mortality: A cohort study.

  2023cites this paper
• Familial hypercholesterolaemia in UK primary care: a Clinical Practice Research Datalink study of an under-recognised condition

  2023cites this paper
• Longitudinal Trends in Severe Dyslipidemia in the Czech Population: The Czech MONICA and Czech Post-MONICA Study

  2023cites this paper
• Lipid metabolic links between serum pyrethroid levels and the risk of incident type 2 diabetes: A mediation study in the prospective design.

  2023cites this paper
• Trends and hotspots in familial hypercholesterolemia: A bibliometric systematic review from 2002 to 2022

  2023cites this paper
• Familial hypercholesterolaemia

  2023cites this paper
• Cross-sectional survey of attitudes and beliefs towards dementia risk reduction among Australian older adults

  2023cites this paper
• Awareness of risk factors for cerebrovascular diseases among acute ischemic stroke patients in Shenzhen, China

  2023cites this paper
• Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.

  2023cites this paper
• Пацієнти високого серцево-судинного ризику у практиці лікаря первинної ланки

  2023cites this paper
• The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population

  2023cites this paper
• Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here

  2023cites this paper
• Disparities in statin prescription among patients with severe hypercholesterolemia in an integrated healthcare system.

  2023cites this paper
• Evolving Management Paradigm for Stable Ischemic Heart Disease Patients: JACC Review Topic of the Week.

  2023cites this paper
• The burden of severe hypercholesterolemia and familial hypercholesterolemia in a population-based setting in the US

  2022cites this paper
• Underdiagnosis of familial hypercholesterolaemia: innovation is overdue.

  2022cites this paper
• Secondary Prevention Using Cholesterol-Lowering Medications in Patients with Prior Atherosclerotic Cardiovascular Disease Events: A Retrospective Cohort Analysis

  2022cites this paper
• Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome.

  2022cites this paper
• Applying an LDL-C threshold-based approach to identify individuals with familial hypercholesterolemia.

  2022cites this paper
• Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35-75 years: Results from China PEACE Million Persons Project.

  2022cites this paper
• Gaps in knowledge and practice for familial hypercholesterolemia among physicians caring for children in Saudi Arabia.

  2022cites this paper
• Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults

  2022cites this paper
• 2022 Taiwan lipid guidelines for primary prevention.

  2022cites this paper
• Leveraging Healthcare System Data to Identify High-Risk Dyslipidemia Patients

  2022cites this paper
• Factors predicting statin initiation during childhood in familial hypercholesterolemia: importance of genetic diagnosis.

  2022cites this paper
• Remnant cholesterol is associated with cardiovascular mortality

  2022cites this paper
• Prevalence and Treatment of Familial Hypercholesterolemia and Severe Hypercholesterolemia in Older Adults in Ontario, Canada

  2022cites this paper
• Familial Hypercholesterolemia Among Young Adults With Acute Coronary Syndrome.

  2022cites this paper
• Influencing Appropriate Statin Use in a Charity Care Primary Clinic

  2022cites this paper
• The effect of total cholesterol/high-density lipoprotein cholesterol ratio on mortality risk in the general population

  2022cites this paper
• Trends and influence factors in the prevalence, intervention, and control of metabolic syndrome among US adults, 1999–2018

  2022cites this paper
• Bridging the Knowledge Gap in the Management of Dyslipidemia: A Quality Improvement Project

  2022cites this paper
• Associations between TUBB-WWOX SNPs, their haplotypes, gene-gene, and gene-environment interactions and dyslipidemia

  2021cites this paper
• Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach.

  2021cites this paper
• Hypercholesterolemia at a young age

  2021cites this paper
• Lower‐Intensity Statins Contributing to Gaps in Care for Patients With Primary Severe Hypercholesterolemia

  2021cites this paper
• Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland

  2021cites this paper
• Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality

  2021cites this paper
• Barriers in utilizing lipid-lowering agents in non-institutionalized population in the U.S.: Application of a theoretical framework.

  2021cites this paper
• Metabolic Syndrome and Osteoarthritis Distribution in the Hand Joints: A Propensity Score Matching Analysis From the Osteoarthritis Initiative

  2021cites this paper
• Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia

  2021cites this paper
• Closing the gap: Identification and management of familial hypercholesterolemia in an integrated healthcare delivery system.

  2021cites this paper
• The U-Shaped Association of Non-High-Density Lipoprotein Cholesterol Levels With All-Cause and Cardiovascular Mortality Among Patients With Hypertension

  2021cites this paper
• Achilles Tendon Thickness Assessed by X-ray Predicting a Pathogenic Mutation in Familial Hypercholesterolemia Gene

  2021cites this paper
• Coronary Heart Disease Risk Associated with Primary Isolated Hypertriglyceridemia; a Population‐Based Study

  2021cites this paper
• Improving Familial Hypercholesterolemia Diagnosis Using an EMR-based Hybrid Diagnostic Model

  2021cites this paper
• Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy

  2021cites this paper
• Atherogenic Dyslipidemia After Liver Transplantation: Mechanisms and Clinical Implications

  2021cites this paper
• Familial Hypercholesterolemia Identification Algorithm in Patients with Acute Cardiovascular Events in A Large Hospital Electronic Database in Bulgaria: A Call for Implementation

  2021cites this paper
• Evolution and Outcomes of Premature Coronary Artery Disease

  2021cites this paper
• Massive data screening is a second opportunity to improve the management of patients with familial hypercholesterolemia phenotype.

  2021cites this paper
• Awareness, treatment rates, and compliance to treatment in patients with serum LDL cholesterol higher than 250 mg/dL, and possible, probable, or definite familial hypercholesterolemia

  2020cites this paper